29 March 2019 3 Min Read
AstraZeneca in huge deal with Daiichi over breast-cancer therapy
The deal on the drug known as trastuzumab deruxtecan sent shares in Japan's Daiichi soaring 16%, its daily limit, to a record high on Friday
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In